Open Access Open Badges Research article

Polysaccharides from the root of Angelica sinensis promotes hematopoiesis and thrombopoiesis through the PI3K/AKT pathway

Chang Liu23*, Jianqin Li2, Fan Yi Meng1, Simon X Liang5, Ruixia Deng3, Chi Kong Li6, NH Pong6, Ching Po Lau6, Sau Wan Cheng6, Jie Yu Ye3, Jian L Chen3, ST Yang3, Haixia Yan2, Shilin Chen2, Beng H Chong5 and Mo Yang134*

Author Affiliations

1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China

2 Institute of Medicinal Plant Development, Chinese Academy of Medical Science, 151 MaLianWa North Road, Beijing, 100193, PR China

3 LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, PR China

4 The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China

5 Center for Vascular Research, Department of Hematology, St George Hospital, University of New South Wales, Sydney, Australia

6 The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, PR China

For all author emails, please log on.

BMC Complementary and Alternative Medicine 2010, 10:79  doi:10.1186/1472-6882-10-79

Published: 21 December 2010



Dozens of Traditional Chinese Medicine (TCM) formulas have been used for promotion of "blood production" for centuries, and we are interested in developing novel thrombopoietic medicines from these TCMs. Our previous studies have demonstrated the hematopoietic effects of DangGui BuXue Tong (DBT), a formula composed of Radix Angelicae Sinensis and Radix Astragali in animal and cellular models. As a step further to identify and characterize the active chemical components of DBT, we tested the hematopoietic and particularly, thrombopoietic effects of polysaccharide-enriched fractions from the root of Radix Angelicae Sinensis (APS) in this study.


A myelosuppression mouse model was treated with APS (10 mg/kg/day). Peripheral blood cells from APS, thrombopoietin and vehicle-treated samples were then counted at different time-points. Using the colony-forming unit (CFU) assays, we determined the effects of APS on the proliferation and differentiation of hematopoietic stem/progenitor cells and megakaryocytic lineages. Using a megakaryocytic cell line M-07e as model, we analyzed the cellular apoptosis progression with and without APS treatment by Annexin V, Mitochondrial Membrane Potential and Caspase 3 assays. Last, the anti-apoptotic effect of APS on cells treated with Ly294002, a Phosphatidylinositol 3-Kinse inhibitor (PI3K) was also tested.


In animal models, APS significantly enhanced not only the recovery of platelets, other blood cells and their progenitor cells, but also the formation of Colony Forming Unit (CFU). In M-07e cells, we observed the anti-apoptotic effect of APS. Treatment by Ly294002 alone increased the percentage of cells undergoing apoptosis. However, addition of APS to Ly294002-treated cells significantly reduced the percentage of cells undergoing apoptosis.


APS promotes hematopoiesis and thrombopoiesis in the mouse model. This effect likely resulted from the anti-apoptosis activity of APS and is likely to involve the PI3K/AKT pathway.